Pomerantz Law Firm Probes Edgewise Therapeutics for Investor Claims Amid SEC Violations
Investor Alert: Pomerantz Law Firm Investigates Edgewise Therapeutics
New York, NY – July 7, 2025
In recent news, Pomerantz LLP has initiated an investigation on behalf of shareholders of Edgewise Therapeutics, Inc., which is publicly traded under NASDAQ symbol EWTX. This action arises from allegations of potential securities fraud and other possibly unlawful practices conducted by the company and certain individuals within its management. Investors who believe they have been affected are encouraged to reach out to Danielle Peyton of Pomerantz at [email protected] or by calling (646) 581-9980, extension 7980.
The investigation primarily focuses on a press release issued by Edgewise on June 26, 2025, where the firm shared data from clinical trials regarding its primary asset, sevasemten. This drug targets Becker and Duchenne muscular dystrophies, conditions that have long challenged medical professionals. While Edgewise claimed that the trial results were
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.